namilumab
Phase 2- Indications
- Ankylosing spondylitis, Rheumatoid arthritis
Company intelligence / Profile preview
Izana Bioscience
London, England, United Kingdomprnewswire.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Namilumab, a human monoclonal antibody targeting GM-CSF, has shown efficacy in a phase II proof-of-concept trial in over 100 rheumatoid arthritis patients and was well tolerated. The company has received Innovate UK funding to support further phase II studies in ankylosing spondylitis. Preclinical work continues on orally delivered mitochondrial protective agents for rare diseases
- Therapeutic areas
- Rare DiseasesRheumatologyImmunology
- Modalities
- Monoclonal antibodies (notably namilumab)Mitochondrial protective therapeutics (preclinical)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Takeda Pharmaceutical Company – exclusive worldwide license agreement for namilumab development/manufacture/commercialization and strategic equity stake.
Beyond the preview
Go deeper on Izana Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Izana Bioscience.